Nectar Lifesciences Fair Value
Nectar Lifesciences fair value. Nectar Lifesciences (NECLIFE) average fair value is ₹370.45 across 4 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹10.95 (+3283.08%), fair value range ₹1.29–₹895.97. Check Nectar Lifesciences marketcap in USD to track the company's total market size over time.
Fair Value Analysis Export
NECLIFE Fair Value vs Current Price — Valuation Summary
NECLIFE average fair value, fair value range, price gap and valuation status across 4 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF). Explore Nectar Lifesciences intrinsic worth to estimate fundamental worth using multiple valuation models.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Discounted Cash Flow (DCF)
NECLIFE Fair Value Analysis — Data Sources & Coverage
Nectar Lifesciences financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit Nectar Lifesciences share price screener.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
NECLIFE vs Healthcare Sector Peers — P/E, P/B & Market Cap
Nectar Lifesciences P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Divis Laboratories | DIVISLAB | 84.36 | 14.72 | ₹244,125 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Syngene International | SYNGENE | 65.37 | 2.98 | ₹14,538 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.